tetano
Editor, Senior Moderator
J Med Virol
. 2021 Apr 29.
doi: 10.1002/jmv.27044. Online ahead of print.
Lack of Immune Response After mRNA Vaccination to SARS-CoV-2 in a Solid Organ Transplant Patient
D S Rusk[SUP] 1 [/SUP], C C Strachan[SUP] 1 [/SUP], B R Hunter[SUP] 1 [/SUP]
Affiliations
Abstract
The recent approval and distribution of vaccines against SARS-CoV-2 has been a major development in the fight against the current COVID-19 pandemic. The first 2 vaccines approved in the United States, mRNA-1273 and BNT162b2, are both mRNA based and highly effective in immunocompetent persons, but efficacy in patients on immunosuppressants has not been established. Additionally, data suggests these patients are less likely that immunocompetent people to develop neutralizing antibodies after COVID-19 infection. Given the high risk of poor outcomes in organ transplant and immunosuppressed patients, effective vaccination is paramount in this group. We present the first reported case of a SOT patient who failed to achieve seroconversion after 2 doses of mRNA vaccine. This case has significant implications about how immunosuppressed patients should be counseled about SARS-CoV-2 vaccination and the protection provided. Physicians should remain clinically suspicious for infection with SARS-CoV-2 despite vaccination status in solid organ transplant patients. This article is protected by copyright. All rights reserved.
Keywords: Disease control; Epidemiology; Immnopathology; Immune responses; Neutralization; SARS coronavirus; Systemic immunity; Transplantation; Vaccines/Vaccine strains; Virus classification.
. 2021 Apr 29.
doi: 10.1002/jmv.27044. Online ahead of print.
Lack of Immune Response After mRNA Vaccination to SARS-CoV-2 in a Solid Organ Transplant Patient
D S Rusk[SUP] 1 [/SUP], C C Strachan[SUP] 1 [/SUP], B R Hunter[SUP] 1 [/SUP]
Affiliations
- PMID: 33913552
- DOI: 10.1002/jmv.27044
Abstract
The recent approval and distribution of vaccines against SARS-CoV-2 has been a major development in the fight against the current COVID-19 pandemic. The first 2 vaccines approved in the United States, mRNA-1273 and BNT162b2, are both mRNA based and highly effective in immunocompetent persons, but efficacy in patients on immunosuppressants has not been established. Additionally, data suggests these patients are less likely that immunocompetent people to develop neutralizing antibodies after COVID-19 infection. Given the high risk of poor outcomes in organ transplant and immunosuppressed patients, effective vaccination is paramount in this group. We present the first reported case of a SOT patient who failed to achieve seroconversion after 2 doses of mRNA vaccine. This case has significant implications about how immunosuppressed patients should be counseled about SARS-CoV-2 vaccination and the protection provided. Physicians should remain clinically suspicious for infection with SARS-CoV-2 despite vaccination status in solid organ transplant patients. This article is protected by copyright. All rights reserved.
Keywords: Disease control; Epidemiology; Immnopathology; Immune responses; Neutralization; SARS coronavirus; Systemic immunity; Transplantation; Vaccines/Vaccine strains; Virus classification.